Lidocaine is a local anesthetic agent used in the form of injection and topical cream. However, these formulation types have limitations of being either painful or slow-acting, thereby hindering effective and complete clinical performance of lidocaine. Dissolving microneedles (DMNs) are used to overcome these limitations owing to their fast onset time and minimally invasive administration methods. Using hyaluronic acid and lidocaine to produce the drug solution, a lidocaine HCl encapsulated DMN (Li-DMN) was fabricated by centrifugal lithography. The drug delivery rate and local anesthetic quality of Li-DMNs were evaluated using the pig cadaver insertion test and Von Frey behavior test. Results showed that Li-DMNs could deliver sufficient lidocaine for anesthesia that is required to be utilized for clinical level. Results from the von Frey test showed that the anesthetic effect of Li-DMNs was observed within 10 min after administration, thus confirming fast onset time. A toxicity test for appropriate clinical application standard was conducted with a microbial limit test and an animal skin irritation test, showing absence of skin irritation and irritation-related microorganisms. Overall, Li-DMN is a possible alternative drug delivery method for local anesthesia, meeting the requirements for clinical conditions and overcoming the drawbacks of other conventional lidocaine administration methods.
|Number of pages||13|
|Publication status||Published - 2020 Nov|
Bibliographical noteFunding Information:
This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16C0625) and a grant of the Korea Startup Scale-Up Package through the Ministry of SMEs & Startups and KISED, Republic of Korea (grant number: 10220767).
Funding: This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16C0625) and a grant of the Korea Startup Scale-Up Package through the Ministry of SMEs & Startups and KISED, Republic of Korea (grant number: 10220767) Conflicts of Interest: D.J.U., J.S., C.L. and U.-W.J. declare no conflict of interest. H.Y., G.K., M.J., H.K., J.H., H.A, and S.G. are employees of JUVIC Inc., which develops microneedle-based products and H.J. is an inventor of patents that have been or may be licensed to JUVIC Inc. and is a shareholder of JUVIC Inc. These potential conflicts of interest have been disclosed and are being managed by Yonsei University. The company had no role in the writing of the manuscript, and in the decision to publish the results.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science